Table 2.
Patient characteristics
| Age at diagnosis | Years |
| Mean | 69.2 |
| Median | 71 |
| Range | 46–86 |
| PSA level pre‐treatment | ng/mL |
| Mean | 8.2 |
| Median | 6.9 |
| Range | 1.69–23.16 |
| Risk category | n (%) |
| Low | 11 (24.4) |
| Intermediate | 28 (62.3) |
| High | 6 (13.3) |
| T stage | n (%) |
| T1 | 22 (49) |
| T2a | 13 (29) |
| T2b | 6 (13) |
| T2c | 2 (4) |
| T3a | 1 (2) |
| T4 | 1 (2) |
| Gleason score | n (%) |
| 6 | 16 (36) |
| 7 (3 + 4) | 20 (44) |
| 7 (4 + 3) | 7 (16) |
| 8 | 1 (2) |
| 9 (4 + 5) | 1 (2) |
| Hormone treatment | n (%) |
| Yes | 7 (16) |
| No | 38 (84) |
| Patient's residence | n |
| Regional (<200 km) | 29 (64) |
| Remote (>200 km) | 16 (36) |